MEZHDURECHENSK, Russia, March 13, 2017 -- Mechel PAO (MICEX:MTLR) (NYSE:MTL), one of the leading Russian mining and metals companies, reports launching a new longwall at V.I. Lenina Underground Mine which is part of Southern Kuzbass Coal Company.
V.I. Lenina Underground launched Longwall 0-5-2-13, whose industrial coal reserves are estimated at 369,000 tonnes of valuable coking coal grades. The longwall is 120 meters long, the extraction panel is 630 meters.
Its coal will be supplied to Russian steelmakers.
Mining at the longwall will be conducted by a stoping complex including a stoping machine, a longwall conveyor and a re-loader with a crushing station. The powered support system’s 84 sections are hydraulically equipped. All equipment is up to modern safety standards. Investment in the project totaled 270 million rubles.
“The launch of this new longwall will enable us to quickly boost production of coking coal which is high in market demand,” Mechel Mining Management OOO’s Chief Executive Officer Pavel Shtark noted.
Mechel is an international mining and steel company which employs 66,000 people. Its products are marketed in Europe, Asia, North and South America, Africa. Mechel unites producers of coal, iron ore concentrate, steel, rolled products, ferroalloys, heat and electric power. All of its enterprises work in a single production chain, from raw materials to high value-added products.
Some of the information in this press release may contain projections or other forward-looking statements regarding future events or the future financial performance of Mechel, as defined in the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. We wish to caution you that these statements are only predictions and that actual events or results may differ materially. We do not intend to update these statements. We refer you to the documents Mechel files from time to time with the U.S. Securities and Exchange Commission, including our Form 20-F. These documents contain and identify important factors, including those contained in the section captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” in our Form 20-F, that could cause the actual results to differ materially from those contained in our projections or forward-looking statements, including, among others, the achievement of anticipated levels of profitability, growth, cost and synergy of our recent acquisitions, the impact of competitive pricing, the ability to obtain necessary regulatory approvals and licenses, the impact of developments in the Russian economic, political and legal environment, volatility in stock markets or in the price of our shares or ADRs, financial risk management and the impact of general business and global economic conditions.
Mechel PAO Ekaterina Videman Tel: + 7 495 221 88 88 [email protected]


Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Bain Capital Moves to Acquire Majority Stake in Echo Marketing
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 



